XML 24 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statement of Equity - USD ($)
$ in Thousands
Total
Cumulative effect of change in accounting principle
Total National Health Investors Stockholders’ Equity
Total National Health Investors Stockholders’ Equity
Cumulative effect of change in accounting principle
Common Stock
Capital in Excess of Par Value
Cumulative Dividends in Excess of Net Income
Cumulative Dividends in Excess of Net Income
Cumulative effect of change in accounting principle
Accumulated Other Comprehensive Income (Loss)
Noncontrolling Interests
Beginning balance (in shares) at Dec. 31, 2019         44,587,486          
Beginning balance, amount at Dec. 31, 2019 $ 1,498,252   $ 1,497,631   $ 446 $ 1,505,948 $ (5,331)   $ (3,432) $ 621
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Noncontrolling interests capital contribution (10,791)                 (10,791)
Distributions declared to noncontrolling interests (886)                 (886)
Total comprehensive income 181,594   181,409       185,126   (3,717) 185
Issuance of common stock, net (in shares)         535,990          
Issuance of common stock, net 34,649   34,649   $ 5 34,644        
Taxes remitted on employee stock awards (2,705)   (2,705)     (2,705)        
Shares issued on stock options exercised (1)   (1)   $ 1 (2)        
Shares issued on stock options exercised, shares (in shares)         62,516          
Share-based compensation 3,061   3,061     3,061        
Dividends declared (197,585)   (197,585)       (197,585)      
Ending balance (in shares) at Dec. 31, 2020         45,185,992          
Ending balance, amount at Dec. 31, 2020 $ 1,522,945 $ (4,225) 1,512,234 $ (4,225) $ 452 1,540,946 (22,015) $ (4,225) (7,149) 10,711
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Change in Accounting Principle, Type [Extensible Enumeration] Accounting Standards Update 2016-13                  
Distributions declared to noncontrolling interests $ (974)                 (974)
Total comprehensive income $ 119,116   118,953       111,804   7,149 163
Issuance of common stock, net (in shares) 661,951       661,951          
Issuance of common stock, net $ 47,904   47,904   $ 7 47,897        
Equity component in redemption of convertible notes (6,076)   (6,076)     (6,076)        
Shares issued on stock options exercised, shares (in shares)         2,656          
Share-based compensation 8,415   8,415     8,415        
Dividends declared $ (174,347)   (174,347)       (174,347)      
Ending balance (in shares) at Dec. 31, 2021 45,850,599       45,850,599          
Ending balance, amount at Dec. 31, 2021 $ 1,516,983   1,507,083   $ 459 1,591,182 (84,558)   0 9,900
Increase (Decrease) in Stockholders' Equity [Roll Forward]                    
Distributions declared to noncontrolling interests (1,015)                 (1,015)
Total comprehensive income 65,501                  
Total comprehensive income, excluding a loss of $843 attributable to redeemable noncontrolling interest 66,344   66,403       66,403     (59)
Issuance of common stock, net (80)   (80)     (80)        
Taxes remitted on employee stock awards (288)   (288)     (288)        
Reclassification of redeemable noncontrolling interest 1,030                 1,030
Shares issued on stock options exercised, shares (in shares)         6,497          
Share-based compensation 8,613   8,613     8,613        
Repurchases of common stock $ (151,951)   (151,951)   $ (25)   (151,926)      
Stock repurchased during period (in shares) (2,468,354)       (2,468,354)          
Dividends declared $ (159,555)   (159,555)       (159,555)      
Ending balance (in shares) at Dec. 31, 2022 43,388,742       43,388,742          
Ending balance, amount at Dec. 31, 2022 $ 1,280,081   $ 1,270,225   $ 434 $ 1,599,427 $ (329,636)   $ 0 $ 9,856